



## PRESS RELEASE

### **Indoco's Revenue Growth at 12%, EBIDTA Jumps 64 % in Q4FY21**

**Mumbai, 25<sup>th</sup> May, 2021:** During the fourth quarter of FY 2020-21, Indoco Remedies revenues grew by 12.0 % at Rs. 294.8 crores, as against Rs. 263.2 crores, same quarter last year. EBIDTA to net sales for the quarter is 18.5 % at Rs. 54.6 crores, compared to 12.7 % at Rs. 33.3 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 8.4 % at Rs. 24.9 crores, compared to 2.1 % at Rs.5.4 crores, same quarter last year.

For the year ended March'21, the Company's revenues grew by 12.8 % at Rs. 1217.4 crores, as against Rs. 1079.4 crores, last year. EBIDTA to net sales is 18.4 % at Rs. 223.6 crores, compared to 11.4 % at Rs. 123.3 crores, last year. The Profit After Tax to net sales is 7.6 % at Rs. 92.4 crores, compared to 2.2 % at Rs. 24.2 crores, last year.

***Commenting on the fourth quarter FY21 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "Revenues from International business continue to register a healthy growth, however, India business has witnessed environmental challenges. The trend in EBIDTA growth has been consistent and encouraging".***

For the quarter ended March'21, the financials are as under: (Rs. in Crores)

Particulars	Jan'21-Mar'21	Jan'20-Mar'20	Gw %
Net Revenues	294.8	263.2	12.0
EBIDTA	54.6	33.3	63.7
Operating Profit	47.9	21.3	124.5
Profit After Tax	24.9	5.4	361.3
EPS (Face value Rs. 2/-)	2.70	0.59	

For the year ended March'21, the financials are as under: (Rs. in Crores)

Particulars	Apr'21-Mar'21	Apr'20-Mar'20	Gw %
Net Revenues	1217.4	1079.4	12.8
EBIDTA	223.6	123.3	81.3
Operating Profit	187.9	76.0	147.3
Profit After Tax	92.4	24.2	281.0
EPS (Face value Rs. 2/-)	10.03	2.63	

**About Indoco Remedies Limited:**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 166 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM, Methycal, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

**For Media inquiries, please contact:**

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)